GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Days Sales Outstanding

CVRx (CVRX) Days Sales Outstanding : 56.19 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is CVRx Days Sales Outstanding?

CVRx's average Accounts Receivable for the three months ended in Dec. 2023 was $6.96 Mil. CVRx's Revenue for the three months ended in Dec. 2023 was $11.31 Mil. Hence, CVRx's Days Sales Outstanding for the three months ended in Dec. 2023 was 56.19.

The historical rank and industry rank for CVRx's Days Sales Outstanding or its related term are showing as below:

CVRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.94   Med: 60.3   Max: 65.5
Current: 60.54

During the past 5 years, CVRx's highest Days Sales Outstanding was 65.50. The lowest was 41.94. And the median was 60.30.

CVRX's Days Sales Outstanding is ranked better than
54.03% of 807 companies
in the Medical Devices & Instruments industry
Industry Median: 64.61 vs CVRX: 60.54

CVRx's Days Sales Outstanding declined from Dec. 2022 (68.67) to Dec. 2023 (56.19).


CVRx Days Sales Outstanding Historical Data

The historical data trend for CVRx's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Days Sales Outstanding Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
41.94 60.30 53.77 65.50 60.63

CVRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.67 68.26 63.20 56.85 56.19

Competitive Comparison of CVRx's Days Sales Outstanding

For the Medical Devices subindustry, CVRx's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CVRx's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where CVRx's Days Sales Outstanding falls into.



CVRx Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

CVRx's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (5.504 + 7.551) / 2 ) / 39.295*365
=6.5275 / 39.295*365
=60.63

CVRx's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (6.372 + 7.551) / 2 ) / 11.305*365 / 4
=6.9615 / 11.305*365 / 4
=56.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CVRx  (NAS:CVRX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


CVRx Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of CVRx's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


CVRx (CVRX) Business Description

Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445